Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation

Lien, Vegard Torp; Kristiansen, Margrethe Konstanse; Pettersen, Solveig; Haugen, Mads H.; Olberg, Dag Erlend; Waaler, Jo; Klaveness, Jo

doi:10.1039/c9ra08954c

Cited by 4 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It resulted in the shortlisting of three drug candidates as potential binders, i.e., CMNPD3609 (Marine), Malyngamide V (Cyanobactin), and ZINC06804365 (Streptomycin metabolite) to inhibit F. nucleatum . The ZINC06804365 has been tested and reported as a potential inhibit for many signaling pathways such as Wnt-3a and also as having inhibitory activity against the Tankyrase-2 enzyme which reportedly has anti-cancer activities [ 74 ]. Malyngamide V has been widely studied for its anti-inflammatory and antinociceptive role [ 75 ] and CMNPD3609 possesses several antibacterial activities [ 76 ].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Target Identification and Inhibitor Screening against Riboflavin Synthase of Colorectal Cancer Associated Fusobacterium nucleatum

Alturki

Mashraqi

Jalal

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) ranks third among all cancers in terms of prevalence. There is growing evidence that gut microbiota has a role in the development of colorectal cancer. Fusobacterium nucleatum is overrepresented in the gastrointestinal tract and tumor microenvironment of patients with CRC. This suggests the role of F. nucleatum as a potential risk factor in the development of CRC. Hence, we aimed to explore whole genomes of F. nucleatum strains related to CRC to predict potential therapeutic markers through a pan-genome integrated subtractive genomics approach. In the current study, we identified 538 proteins as essential for F. nucleatum survival, 209 non-homologous to a human host, and 12 as drug targets. Eventually, riboflavin synthase (RiS) was selected as a therapeutic target for further processing. Three different inhibitor libraries of lead-like natural products, i.e., cyanobactins (n = 237), streptomycins (n = 607), and marine bacterial secondary metabolites (n = 1226) were screened against it. After the structure-based study, three compounds, i.e., CMNPD3609 (−7.63) > Malyngamide V (−7.03) > ZINC06804365 (−7.01) were prioritized as potential inhibitors of F. nucleatum. Additionally, the stability and flexibility of these compounds bound to RiS were determined via a molecular dynamics simulation of 50 ns. Results revealed the stability of these compounds within the binding pocket, after 5 ns. ADMET profiling showed compounds as drug-like, non-permeable to the blood brain barrier, non-toxic, and HIA permeable. Pan-genomics mediated drug target identification and the virtual screening of inhibitors is the preliminary step towards inhibition of this pathogenic oncobacterium and we suggest mouse model experiments to validate our findings.

show abstract

Section: Discussionmentioning

confidence: 99%